Latest Regulatory News

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

Pure Hydrogen Corporation has secured a 15-year Potential Commercial Area approval and extended its ATP 927 permit for the Windorah Gas Project, marking a critical regulatory milestone ahead of its planned spinout.

Arika Resources has identified 17 new high-priority gold targets at its Kookynie Gold Project in Western Australia, leveraging advanced ultrafine soil geochemistry. These untested targets could unlock significant exploration upside in a prolific gold district.

FirstWave Cloud Technology has secured a strategic partnership with Amazon Web Services and Corent Technology to launch its IT compliance and network management software on the AWS Marketplace within weeks, aiming to expand its global reach and monetise its large user base.

Dateline Resources secures high-level U.S. government backing to accelerate its Colosseum Rare Earths Project in California, highlighting its strategic role in domestic critical minerals supply.

Falcon Metals has initiated diamond drilling at the Blue Moon target, aiming to unlock extensions of the historically rich Garden Gully anticline near Bendigo. Results expected by August 2025 could reshape exploration prospects in Victoria’s prolific gold belt.

Eclipse Metals has successfully raised $2 million through an oversubscribed placement at market price, aiming to accelerate exploration and environmental work at its Grønnedal rare earth project in Greenland.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Cygnus Metals has clarified that its recent share price and volume spike stemmed from new assay results at its Golden Eye prospect and broader copper sector dynamics, confirming compliance with ASX disclosure rules.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Hutchison Telecommunications (Australia) Limited (HTAL) has recommended shareholders accept an off-market takeover bid by majority owner HTABV, offering a significant premium over recent trading prices. Independent experts affirm the offer as fair and reasonable, setting the stage for a potential full acquisition.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.